Guardant Health Inc (GH)

R&D to Revenue

28.82%

Quarterly · Period ending:

GH logo

GH R&D to Revenue

Latest reported28.82%
GH Quarterly R&D/Revenue (57.09% → 28.82%)
High-resolution chart · PNG

GH r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Guardant Health Inc R&D to Revenue — Quarterly
Period endingR&D to Revenue
28.8177%
30.1785%
34.9363%
33.9209%
37.6792%
43.5055%
46.3511%
45.5963%
46.888%
49.7368%
57.9514%
65.6163%
65.8833%
72.3527%
83.9918%
85.1905%
78.2956%
85.0758%
67.5445%
74.8773%
69.1893%
70.5625%
51.4352%
48.606%
54.7509%
54.8304%
41.1387%
40.3777%
36.1871%
44.5123%
50.6556%
65.7063%
59.612%
49.4548%
40.5959%
65.0916%
58.6014%
57.0879%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.